Chat with us, powered by LiveChat

Past

Identifying the formation of nitrosamines via degradation pathways using an in-silico approach

Ensuring the safety of active pharmaceutical ingredients (APIs) is of great importance. A critical aspect of this process involves the identification and mitigation of potentially mutagenic impurities, like nitrosamines. Our in silico tool Zeneth has been used within exploratory formulation departments to understand and account for potential degradation problems within the API at an early stage, resulting […]

Identifying the formation of nitrosamines via degradation pathways using an in-silico approach Read More »

BTS Annual Congress

We were delighted to attend British Toxicology Society Annual Congress 2024 at Spaces at The Spine, Liverpool. The British Toxicology Society (BTS) promotes the importance and advancement of toxicology in scientific communities. During the conference, Lhasa Principal Scientist, Robert Foster, presented a poster titled “Computational modelling of genotoxicity assays: challenges & opportunities”. Robert also gave

BTS Annual Congress Read More »

Genetic Toxicology Association Annual Meeting

The Genetic Toxicology Association (GTA) held its annual scientific meeting April 10-12th, in Delaware, Newark. Principal Scientist, Susanne Stalford presented a poster in collaboration with Toxys, the poster is titled ‘Association of the ToxTracker® Assay to Genotoxicity Adverse Outcome Pathways’. ToxTracker® is a next generation stem-cell based assay that utilises a combination of six unique fluorescent

Genetic Toxicology Association Annual Meeting Read More »

8th Impurities: Genotoxic, Nitrosamine & Beyond Summit

We were delighted to attend the 8th Impurities: Genotoxic, Nitrosamine & Beyond Summit. Senior Application Scientist, Gabriela Silveira presented ‘Accelerating nitrosamine risk assessment: Meeting emerging regulatory guidelines’. In this talk, she discussed: – Use of in-silico tools on nitrosamine risk assessments – How data sharing and collaboration aid in nitrosamines assessments – Setting AIs using

8th Impurities: Genotoxic, Nitrosamine & Beyond Summit Read More »

9th German Pharm-Tox Summit

We were delighted to attend the 9th German Pharm-Tox Summit, on March 13–15, 2024, in Munich, Germany. The GPTS is organized by the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) together with the Austrian Society of Toxicology (ASTOX), Austrian Pharmacological Society (APHAR) and the Association for Applied Human Pharmacology (AGAH). The program,

9th German Pharm-Tox Summit Read More »

51st Organic Process Research and Development

The 51st OPRD Conference was held in San Deigo! The event provided scientific content alongside the renowned networking receptions. Lhasa joined others in this fantastic location to hear cutting-edge scientific content and the latest scientific updates from industry alongside renowned networking receptions.  We had the chance to connect with other like-minded chemists and benefit from

51st Organic Process Research and Development Read More »

Leachables sensitisation assessment framework in collaboration with ELSIE

This enlightening event brought together esteemed members of the Extractables and Leachables Safety Information Exchange (ELSIE) consortium for a captivating discussion on the sensitisation potential of extractables and leachables (E&Ls). Featured presenters and ELSIE consortium members included: Patricia Parris, Global Risk Assessment Services Toxicologist at Pfizer Geraldine Whelan, Regulatory Toxicologist at GSK Martyn Chilton, Principal

Leachables sensitisation assessment framework in collaboration with ELSIE Read More »

Performing ICH M7 risk assessment for process impurities and degradation products (in Spanish)

Performing ICH M7 risk assessment for process impurities and degradation products was targeted towards Latin America and carried out in Spanish. In this event, we explored how our software solution, Zeneth, can help you to identify potential degradation impurities in your drug development workflow. We also demonstrated how to classify potentially mutagenic impurities through our

Performing ICH M7 risk assessment for process impurities and degradation products (in Spanish) Read More »